About Envisagenics
Envisagenics is a company based in Long Island City (United States) founded in 2014 by Martin Akerman and Maria Luisa Pineda.. Envisagenics has raised $46.78 million across 9 funding rounds from investors including New York State, HHS and Bristol-Myers Squibb. Envisagenics offers products and services including SpliceCore and SpliceIO. Envisagenics operates in a competitive market with competitors including Genomics, Seven Bridges Genomics, Dicerna Pharmaceuticals, Depixus and Ingenuity Systems, among others.
- Headquarter Long Island City, United States
- Founders Martin Akerman, Maria Luisa Pineda
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$46.78 M (USD)
in 9 rounds
-
Latest Funding Round
$25 M (USD), Series B
Jun 05, 2024
-
Investors
New York State
& 15 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Envisagenics
Envisagenics offers a comprehensive portfolio of products and services, including SpliceCore and SpliceIO. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI tool for discovering RNA splicing drug targets
Identifies tumor-specific neoepitopes for therapies
Unlock access to complete
Unlock access to complete
Funding Insights of Envisagenics
Envisagenics has successfully raised a total of $46.78M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series B — $25.0M
-
First Round
First Round
(27 Jul 2015)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2024 | Amount | Series B - Envisagenics | Valuation | Third Kind Venture Capital , New York State |
|
| Jul, 2022 | Amount | Grant - Envisagenics | Valuation |
investors |
|
| Sep, 2021 | Amount | Series A - Envisagenics | Valuation | Red Cell Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Envisagenics
Envisagenics has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include New York State, HHS and Bristol-Myers Squibb. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Technology companies are incubated by Red Cell Partners for critical sectors.
|
Founded Year | Domain | Location | |
|
Venture capital investments in technology startups are facilitated by M12.
|
Founded Year | Domain | Location | |
|
Venture capital investing in AI, biotech, and technology sectors, focusing on seed and early stages in Seattle and beyond.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Envisagenics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Envisagenics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Envisagenics Comparisons
Competitors of Envisagenics
Envisagenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Genomics, Seven Bridges Genomics, Dicerna Pharmaceuticals, Depixus and Ingenuity Systems, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Genomic risk assessment and prevention platform is provided.
|
|
| domain | founded_year | HQ Location |
Cloud-based platform to analyze, store, and act on genomic data.
|
|
| domain | founded_year | HQ Location |
Drugs are developed using RNA interference technology platform.
|
|
| domain | founded_year | HQ Location |
Single-molecule genetic and epigenetic sequencing solutions are provided.
|
|
| domain | founded_year | HQ Location |
Genomic data is analyzed and interpreted via web-based applications.
|
|
| domain | founded_year | HQ Location |
RNAi therapeutics are developed for dermal, ophthalmic, and pulmonary diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Envisagenics
Frequently Asked Questions about Envisagenics
When was Envisagenics founded?
Envisagenics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is Envisagenics located?
Envisagenics is headquartered in Long Island City, United States. It is registered at Long Island City, New York, United States.
Who is the current CEO of Envisagenics?
Maria Luisa Pineda is the current CEO of Envisagenics. They have also founded this company.
Is Envisagenics a funded company?
Envisagenics is a funded company, having raised a total of $46.78M across 9 funding rounds to date. The company's 1st funding round was a Series A of $19.18M, raised on Jul 27, 2015.
What does Envisagenics do?
Envisagenics was founded in 2014 and is based in Long Island City, United States. Operations center on the biotechnology sector, where novel RNA splicing therapeutics are discovered and developed using artificial intelligence. A cloud-based platform called SpliceCore is provided, which has been experimentally validated to predict drug targets and biomarkers via splicing analysis of RNA-seq data.
Who are the top competitors of Envisagenics?
Envisagenics's top competitors include Dicerna Pharmaceuticals, Eagle Genomics and Orna.
What products or services does Envisagenics offer?
Envisagenics offers SpliceCore and SpliceIO.
Who are Envisagenics's investors?
Envisagenics has 16 investors. Key investors include New York State, HHS, Bristol-Myers Squibb, National Cancer Institute, and Red Cell Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.